• 대한암한의학회지
• /
• 제28권1호
• /
• pp.25-31
• /
• 2023

Objectives: With antibiotic resistance one of the biggest threats to global health, we report a case of surgical site infection (SSI) after breast cancer surgery that improved only with the treatment of Taglisodog-eum (托裏消毒飮), Korean herbal medicine, without the use of antibiotics. Methods: The patient diagnosed with ductal carcinoma in situ of left breast underwent nipple areola skin sparing mastectomy and reconstruction using deep inferior epigastric perforator flap. About a month later, superficial SSI occurred at the incision site of breast cancer surgery with general weakness, and Taglisodog-eum treatment was started. To evaluate the effectiveness of the treatment, we compared the infection site conditions before and after treatment. Results: About three weeks after taking Taglisodog-eum, the SSI improved along with the improvement of general weakness. Conclusions: This study shows that Taglisodog-eum may be effective for SSI after breast cancer surgery, and the potential for alternatives to reduce antibiotic use and antibiotic resistance.

• 대한한방내과학회지
• /
• 제44권3호
• /
• pp.594-601
• /
• 2023

Objective: To demonstrate an improvement in metastatic cancer pain and a decrease in tumor size in a patient with non-small cell lung cancer. Method: A 53-year-old female patient diagnosed with metastatic non-small cell lung cancer in August 2022 underwent integrative cancer treatment (ICT) for two months to decrease the tumor size and improve back pain from bone metastasis. The patient underwent chemotherapy with ICT. Radiologic outcomes were assessed by chest, abdomen, and pelvis computed tomography based on the Response Evaluation Criteria in Solid Tumors (RECIST) protocol. Clinical outcomes were assessed using National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), Eastern Cooperative Oncology Group (ECOG), and a numeric rating scale (NRS). Result: During the two months of treatment, the NRS scores for back pain were improved, and the ECOG score improved from grade 2 to 1. The size and metabolic activity of the primary lung tumor decreased and underwent partial remission based on RECIST. No serious side effects of grade 3 or higher were noted on the NCI-CTCAE test. Conclusion: This case suggests that ICT may have a therapeutic effect for cancer pain and a synergetic effect with chemotherapy for metastatic non-small cell lung cancer.

• 대한암한의학회지
• /
• 제24권1호
• /
• pp.11-18
• /
• 2019

Objective: The purpose of this study is to report the effectiveness and possibility of Integrative Cancer Treatment (ICT) on an advanced metastatic leiomyosarcoma patient. Methods: The patient was diagnosed with recurred and advanced metastatic Leiomyosarcoma, suffering from dyspnea, abdominal discomfort, lower limb edema. The patient refused conventional treatment, such as chemotherapy, radiotherapy but was treated with ICT including acupuncture, pharmacopuncture, moxibustion, hypertherapy and herbal medicine for symptom management. The clinical outcomes were measured by NRS (Numeral rating scale). Results: After treatment, dyspnea, abdominal discomfort and lower limb edema was relieved from NRS 6 to 3, 7 to 3 and 7 to 6 respectively. Also, loss of body weight, decrease in abdominal, thigh and calf circumference were improved. During and after treatment, we found neither hepatotoxicity nor nephrotoxicity on laboratory findings. Conclusion: This case study suggests that ICT may improve symptom relief and life quality of leiomyosarcoma patient.

• 대한암한의학회지
• /
• 제24권1호
• /
• pp.19-28
• /
• 2019

Objective : The purpose of this study is to report and observe effects of Integrative Cancer Treatment (ICT) on metastatic breast cancer patient. Method : A left breast cancer patient diagnosed with recurrence on liver and bones April 2018. The patient had received paclitaxel chemotherapy for two months and discontinued it because of tumor progression and side effects. The patient has been treated with ICT since March 2018 and has been taking capecitabine since October 2018. The clinical outcomes were measured by computed tomography, laboratory findings including tumor markers (CEA, CA15-3). The clinical outcomes were measured by computed tomography, laboratory findings including tumor markers (CEA, CA15-3), liver function test (AST, ALT), Eastern Cooperative Oncology Group performance status (ECOG PS), and numeric rating scales (NRS). Results : After the ICT, tumor size was partially decreased accompanying by reducing the levels of tumor markers. Major clinical symptoms induced by paclitaxel chemotherapy were improved. There were no severe adverse events induced by ICT based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Conclusion : This case suggests that ICT may have synergistic effect for the treatment of metastatic breast cancer patient in conjunction with capecitabine.

• 대한한방부인과학회지
• /
• 제37권3호
• /
• pp.33-48
• /
• 2024

Objectives: The purpose of this study is to analyze the effect of Korean-Western medicine integrative care for patients on hospitalized with gynecologic and breast cancer. Methods: The records were searched for integrative medical treatment the Department of Obstetrics and Gynecology in a Korean medical hospital between January 1st, 2021 and April 30, 2024, based on the Electronic Medical Record system (EMR). The records were reviewed and analyzed based on the patient's characteristics, the chief symptom, Korean medical treatment which patients received, and follow-up observation Results: 61 cases were screened, the patient's age is the highest in their 50s with 16 cases (26.23%). The average hospitalization period for patients with integrative care is 7.64 days. Among the patients with integrative care, 60 patients (98.36%) underwent surgery. Gastro-intestinal symptoms (nausea/vomiting, constipation /diarrhea etc.) showed the largest proportion in total symptoms (40.72%). After Korean-medicine integrative treatment, 62.30% of patients improved their symptoms, and 19.67% of cases were not improved because follow-up was not performed. Acupuncture is the most frequently performed Korean-medicine treatment (90.16%), followed by moxibustion (55.74%) and herbal medicine (37.70%). Among the herbal medicines, Gamisipjeon-tang and Geonchil-dan were the two most used herbal medicines. Conclusions: Included cases showed that treatments used in Korean medicine hospitals for integrative care with gynecologic and breast cancer are safe and effective based on several evidence. In the future, further high-quality large-scale study is needed to prove effectiveness of Korean-Western integrative care for patients with gynecologic and breast cancer.

• 대한한방내과학회지
• /
• 제44권3호
• /
• pp.578-584
• /
• 2023

Objectives: This is a five-year survival and complete response (CR) report on rectal cancer treated with western medicine and Korean traditional medicine. Method: A 25-year-old woman diagnosed with rectal cancer visited ⃝⃝ Korean traditional medicine hospital after neoadjuvant concurrent chemoradiation therapy, chemotherapy, and low anterior resection with regional lymph node dissection. She was treated with Korean traditional medicine, including acupuncture, abdominal moxibustion, wild ginseng pharmacopuncture, and herbal medicine, which was based on integrated medicine therapy (IMT), from January 2018 to February 2022. The tumor size was measured by scanning with computed tomography (CT), magnetic resonance imaging, and positron-emission tomography/CT. Adverse events were evaluated using laboratory conclusion and National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Result: During four years of treatment, IMT maintained safety. The patient finally reached five-year survival without any recurrence or complication (CR) on March 11, 2022. Conclusion: We suggest that an integrative approach including Korean traditional medicine can be a meaningful treatment option for rectal cancer. Further studies should be performed to establish the proper treatment protocol of integrative medicine for rectal cancer.

• 대한한의학회지
• /
• 제42권1호
• /
• pp.119-128
• /
• 2021

비소세포성폐암 3기B 진단을 받고, 표준치료인 동시항암방사선치료를 시행했으나 별무효과였던 40대 남자에게, 한양방통합치료를 장기간 집중적으로 시행한 결과, 3개월만에 완전 관해에 도달하고, 5년 생존에 성공함으로써 한양방통합치료의 가능성을 보여 주었기에, 이에 증례를 보고한다.

• 대한암한의학회지
• /
• 제18권1호
• /
• pp.17-22
• /
• 2013

Objectives : The aim of this report is to evaluate antitumor efficacy of Rhus vernifciflua STOKES decoction (Chijong-tang). Methods : One advanced gastric cancer patient with peritoneal seeding and mesenteric metastasis visited Hana integrative Clinic of Korean medicine in Aug 2012 and was treated with Chijong-tang for 14 months. Results : Chijong-tang showed no side effect during its treatment (Aug 2012 ~ Oct 2013) and the patient showed no disease progression. Conclusion : This case report suggests that Rhus vernifciflua Stokes decoction (Chijong-tang) can be a potent anticancer agent for gastric cancer, but it still required further scientific and clinical evidence.

• 대한암한의학회지
• /
• 제11권1호
• /
• pp.1-21
• /
• 2006

This study was undertaken to evaluate safety and antitumor activity of Nexia, a processed extract of Rhus verniciflua STOKES by heating according to Korean patent 0504160 through toxicology, cancer research and clinical application. Nexia did not exhibit any toxicological symptoms through 13 week continuous treatment, dosage accumulation study and anaphylaxis response. The lifespan of four patients with acute lymphocytic leukemia under complete remission were 110, 83, 97, and 86 months after treatment of Nexia, respectively. These data suggest that Nexia, a processed extract by removing allergen from Rhus verniciflua STOKES, may have safety and antitumor activity and also still need continuous study on its mechanism and clinical trial.

• Journal of Applied Biological Chemistry
• /
• 제66권
• /
• pp.379-387
• /
• 2023

Dog owners seek treatment when their pets develop cancer. IMMUNIES is traditional herbal medicine-based figment made of 10 natural herbs, designed to maintain host immune function. The major component of IMMUNIES is Dendropanax morbiferus. This clinical pilot study monitored the toxicity and efficacy of IMMUNIES. Four senile dogs with spontaneously occurring mammary and liver cancers were enrolled in this study and treated orally daily for 3 months, and their blood/urine biochemical profiles were examined each month. IMMUNIES was well tolerated during the treatment period. Blood urea nitrogen, creatinine, alanine aminotransferase, alkaline phosphatase, and C-reactive protein levels decreased in all four dogs, whereas red blood cells and hematocrit were within the normal range. IMMUNIES also changed the expression of several molecular targets in the anticancer pathway, such as pro-NAG-1, p53, and cyclin D1. Although the tumors did not completely respond to IMMUNIES, the biochemical profiles and clinical examination showed a stabilized cancer status for 3 months. Thus, IMMUNIES was found to be safe and well-tolerated in the dosage range tested and exhibited cancer antiproliferative activity in canine cancer. Future studies should address other potential benefits of IMMUNIES, including correlative assessments of immune function, quality of life, and owner satisfaction.